ORIC Pharma Q1 2022: $256.2M cash runways into 2H2024; three Phase 1b data readouts in 1H2023

Oric Pharmaceuticals, Inc.

2023-Q1 EPS reported -$0.59

Cash and investments $256.2M as of March 31, 2022; expected to fund operations into 2H2024.
R&D expenses $16.8M (up $5.1M YoY) driven by advancing ORIC-533, -114, -944; ORIC-101 discontinued.
G&A expenses $6.4M (up $1.6M YoY) due to higher personnel costs.
Three Phase 1b trials (ORIC-533 in multiple myeloma; ORIC-114 in EGFR/HER2; ORIC-944 in prostate) targeting initial data in 1H2023.
PLK4 inhibitor program in lead optimization for TRIM37-amplified breast cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.